chlorambucil and olaparib

chlorambucil has been researched along with olaparib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Badie, S; Baguña Torres, J; Batra, AS; Biroccio, A; Brino, L; Bruna, A; Caldas, C; Cornelissen, B; De Gregoriis, G; Dedic, S; Folio, C; Green, M; Kopp, A; Lai, X; Lee, JW; Leonetti, C; Moore, J; Porru, M; Reisländer, T; Rueda, OM; Ryan, A; Sneddon, D; Tacconi, EM; Tarsounas, M	1

Other Studies

1 other study(ies) available for chlorambucil and olaparib

Article	Year
Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. EMBO molecular medicine, 2019, Volume: 11, Issue:7 Topics: Animals; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Chlorambucil; Cricetinae; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, SCID; Peroxisome Proliferator-Activated Receptors; Phthalazines; Piperazines; Xenograft Model Antitumor Assays	2019

Article

Year

Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.

EMBO molecular medicine, 2019, Volume: 11, Issue:7

Topics: Animals; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Chlorambucil; Cricetinae; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, SCID; Peroxisome Proliferator-Activated Receptors; Phthalazines; Piperazines; Xenograft Model Antitumor Assays

2019